Azafaros

Azafaros is a private, clinical-stage biopharmaceutical company advancing nizubaglustat, a novel oral small molecule with a dual mechanism of action for lysosomal storage disorders. The company has progressed nizubaglustat into Phase 3 pivotal trials for Niemann-Pick type C disease and GM1/GM2 gangliosidoses, building on positive Phase 2 data. Founded on decades of academic research from Leiden University and Amsterdam UMC, Azafaros is backed by a strong syndicate of European life science investors and led by an experienced industry team.

Platform of orally available, brain-penetrant azasugar small molecules designed for dual inhibition of enzymes (GCS and GBA2) in the glycosphingolipid metabolic pathway.

Competition includes other substrate reduction therapies (e.g., miglustat for NPC), investigational gene therapies, and enzyme replacement approaches. Azafaros's differentiation lies in nizubaglustat's oral bioavailability, brain penetration, and novel dual mechanism of action, potentially offering a more comprehensive pharmacological approach.